Head Of Marijuana Advocacy Group Americans For Safe Access Stepping Down

Steph Sherer, who founded the medical marijuana advocacy organization Americans for Safe Access in 2002 and ran it ever since as executive director, is stepping down to pursue a new cannabis career in Europe – becoming the latest high-profile MJ reformer to exit their posts.

Sherer plans to split her time between Washington DC and Prague, the Czech Republic capital, where she’ll serve as president of the International Cannabis and Cannabinoids Institute (ICCI), according to a news release.

The ICCI – which Sherer helped found in 2015 – is a collaboration of patient advocates, scientists and a New York-based investment company Dioscorides Global Holdings. Sherer formed Dioscorides in 2014.

The institute intends to work hand-in-hand with governments, private enterprise and universities to further marijuana and hemp reform around the globe.

“For the last 17 years, I have worked to break down societal and governmental barriers for patients who need access to medical cannabis,” Sherer said in the release.

“Now that these barriers are tumbling down, it is important that industry evolves to provide products for these populations that are safe, standardized and targeted and that there is the scientific infrastructure to support these efforts.”

She will remain as president of the board for Americans for Safe Access, though she’ll relinquish her executive director role.

Sherer’s exit from nonprofit marijuana advocacy follows the departures of other longtime reformers such as Ethan Nadelmann from the Drug Policy Alliance and Rob Kampia from the Marijuana Policy Project.

Original Article Source: https://mjbizdaily.com/head-cannabis-advocacy-group-americans-for-safe-access-stepping-down/

Comments

Could CBD Lead To The Development Of Safer Antipsychotic Medications?

Antipsychotic medications are important for managing a number of different psychiatric ailments, including bipolar disorders, schizophrenia, and even dementia. These drugs can greatly improve the manageability of symptoms that often distort one’s experience of reality. They can also create major mood disruptions and lead to a number of behavioral and emotional difficulties. Antipsychotic and anti-psychosis medications can be life-changing for people with such disorders, enabling them to live more normal and manageable lives without their symptoms taking over. These drugs work by regulating neurotransmitters in the brain so that naturally occurring imbalances and dysfunctions no longer disrupt mental and emotional processes. Often, reaching this outcome is much easier said than done; it can take a lot of time to find courses and combinations of treatments that work. It’s sometimes necessary to make adjustments to find the right balance for the individual and it’s not unusual for outc...

Cannabis Watch: Canopy Growth To Book Charge Of Up To $568 Million As Marijuana Restructuring Continues

Canopy Growth Corp. said early Thursday it was halting a range of operations across three continents and expects its restructuring plans to result in a charge of up to C$800 million (567.9 million) in the fiscal fourth quarter. U.S.-traded shares US:CGC CA:WEED of the cannabis company fell 1.9% in afternoon trading. Canopy said it was selling operations in Africa, curtailing cultivation of hemp in the U.S. and Columbia, and shutting down an indoor production facility in Canada. The announcement will result in 85 job cuts, the company said. “When I arrived at Canopy Growth in January, I committed to conducting a strategic review in order to lower our cost structure and reduce our cash burn,” Canopy Chief Executive David Klein said in a statement. Read: As cannabis industry stays largely quiet on coronavirus, this CEO has been sounding the alarm Canopy’s restructuring announcement was expected by investors, Cowen analyst Vivien Azer wrote in a note to clients Thursday. Azer rate...

Can Medical Marijuana Help Aging Parents With Dementia?

For decades, marijuana, even for medical uses, was demonized or questioned. When states like Colorado legalized it for recreational use, more studies began to determine provable efficacy for its use as a medicine. The Federal government still classifies marijuana the same way it classifies heroin: harmful and with no medical benefits. Now we can see that this is wrong. When states legalized marijuana, referred to as cannabis here, they had an interest in getting data to see what good it could do. Proving efficacy could increase medical marijuana sales, benefit people who might at least find some medical use, and overall would bring tax dollars into the state coffers. Without funding studies, the Federal government has done very little to demonstrate what good cannabis can do. After all, if the presumption is that it helps nothing, there would be no motivation to determine with scientific data that it does anyone any good. But we have convincing data now about its beneficial use ...

Norma Pence

Search This Blog